EPISODE · Feb 13, 2024 · 24 MIN
Ep. 215 - ADCs, Psychedelics & IPOs
from BioCentury This Week · host BioCentury
Innate immunity is getting another shot at cancer through antibody-drug conjugates, with immunostimulatory antibody-drug conjugates moving from concept to clinical product. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how the therapies work and what sets them apart from conventional ADCs.The editors also survey the companies developing psychedelic therapies that aim to overcome the difficulties of the business model, and assess Gilead's $4.3 billion takeout of liver disease company CymaBay, and the performance of IPOs by genomic editing tools company Metagenomi and immunology company Kyverna.Music for The East-West Biopharma Summit: Singapore teaser:Composed by: Moa MichaeliProduced by: Samuel Aneheim Ulvenäs, Albin Lewin, Epidemic Sound via Getty ImagesReach us by sending a text
What this episode covers
Innate immunity is getting another shot at cancer through antibody-drug conjugates, with immunostimulatory antibody-drug conjugates moving from concept to clinical product. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how the therapies work and what sets them apart from conventional ADCs. The editors also survey the companies developing psychedelic therapies that aim to overcome the difficulties of the business model, and assess Gilead's $4.3 billion takeout of liv...
NOW PLAYING
Ep. 215 - ADCs, Psychedelics & IPOs
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m